GLA and chronic hepatitis C virus infection: All three trials included participants with chronic hepatitis C. Manns et al. conducted a phase III trial with 379 participants,49 and found that GLA 1 exhibited a significantly higher alanine transaminase (ALT) reduction compared with placebo after 12 weeks of therapy and improved necro-inflammation and fibrosis after 52 weeks of treatment.